Rigel Pharmaceuticals, Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $42.92
- 52-Week Range
- $24.95 – $52.61
- Market Cap
- $800.84M
- P/E (TTM)
- 2.65
- EPS (TTM)
- 16.07
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.79
- PEG Ratio
- —
- Return on Equity
- 109.18%
- Return on Assets
- 12.35%
- Gross Margin
- 70.69%
- Operating Margin
- 26.28%
- Profit Margin
- 106.59%
- Current Ratio
- 2.39
- Debt/Equity
- 0.02
- Total Debt
- $7.79M
- Free Cash Flow
- $-8.59M
- Revenue Growth
- 16.50%
- Earnings Growth
- -55.50%
- Enterprise Value
- $709.33M
Market Snapshot
About
Rigel Pharmaceuticals is a biotechnology company focused on discovering and developing small molecule drugs for hematologic disorders, cancer, and rare immune diseases. The company has developed approved therapies and maintains a pipeline of clinical and preclinical candidates. Rigel uses its expertise in intracellular signaling pathways to identify novel therapeutic targets.